Comparison of the semisolid agar antifungal susceptibility test with the NCCLS M38-P broth microdilution test for screening of filamentous fungi

Basit Öğe Kaydı
dc.contributor.authorKuzucu, C
dc.contributor.authorRapino, B
dc.contributor.authorMcDermott, L
dc.contributor.authorHadley, S
dc.date.accessioned2024-08-04T20:13:47Z
dc.date.available2024-08-04T20:13:47Z
dc.date.issued2004
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAntifungal susceptibility testing of pathogenic molds is being developed. A simple screening semisolid agar antifungal susceptibility (SAAS) test accurately measures susceptibilities of yeasts. The performance of the SAAS screening test for filamentous fungi was assessed by comparing MICs of four antifungals (amphotericin B [AMB], AMB lipid complex [ABEL], itraconazole [ITZ], and posaconazole [POS]) for 54 clinical mold isolates with the results of the National Committee for Clinical Laboratory Standards (NCCLS) proposed broth microdilution method (M38-P). The SAAS test utilized inocula stabbed into tubes of 0.5% semisolid heart infusion agar. In both tests MICs were read after incubation at 35degreesC for 48 h. The isolates tested were Aspergillus fumigatus, Aspergillus niger, Aspergillus flavus, other Aspergillus spp., Fusarium spp., Penicillium sp., Mucor sp., Scedosporium prolificans, Trichophyton sp., and an unidentified dematiaceous mold. Concordance of test results was determined as the percent agreement of MICs I dilution. The overall agreement between the tests for each drug was as follows: AMB, 94%; ABEL, 83%; ITZ, 94%; POS, 94%. For the Aspergillus spp., all but one were susceptible to ITZ by SAAS test; all were susceptible to POS (MIC range, 0.25 to 4 mug/ml). Three of six non-Aspergillus molds that were resistant to AMB and ABEL by SAAS (MIC greater than or equal to 2 mug/ml) were also resistant by the NCCLS test. The SAAS test compared favorably to the NCCLS broth microdilution test for molds, and most of the clinical isolates tested were susceptible to all four drugs.en_US
dc.identifier.doi10.1128/JCM.42.3.1224-1227.2004
dc.identifier.endpage1227en_US
dc.identifier.issn0095-1137
dc.identifier.issn1098-660X
dc.identifier.issue3en_US
dc.identifier.pmid15004080en_US
dc.identifier.scopus2-s2.0-1542409119en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1224en_US
dc.identifier.urihttps://doi.org/10.1128/JCM.42.3.1224-1227.2004
dc.identifier.urihttps://hdl.handle.net/11616/93848
dc.identifier.volume42en_US
dc.identifier.wosWOS:000220376900045en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAmer Soc Microbiologyen_US
dc.relation.ispartofJournal of Clinical Microbiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInfectionsen_US
dc.titleComparison of the semisolid agar antifungal susceptibility test with the NCCLS M38-P broth microdilution test for screening of filamentous fungien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu